Show simple item record

dc.contributor.authorO'Dwyer, Maire
dc.date.accessioned2024-10-21T04:50:34Z
dc.date.available2024-10-21T04:50:34Z
dc.date.issued2017-06-01
dc.date.submitted2017en
dc.identifier.citationO'Dwyer, M., Peklar, J., Mulryan, N., McCallion, P., McCarron, M., & Henman, M. C., Prevalence, patterns and factors associated with psychotropic use in older adults with intellectual disabilities in Ireland, Journal of Intellectual Disability Research, 61, 10, 2017, 969 - 983en
dc.identifier.otherY
dc.description.abstractBackground: People with intellectual disability (ID) are at increased risk of exposure to psychotropic drugs and psychotropic polypharmacy because of the higher prevalence of mental health conditions present and more controversially, the use of these agents to treat challenging behaviours. Despite the fact that many adults with ID are exposed to psychotropic polypharmacy, few studies to date have focused on the patterns of use of multiple psychotropics, or factors associated with psychotropic polypharmacy, particularly in the older population. This study aims to examine the prevalence, patterns and factors associated with psychotropic use in general and psychotropic polypharmacy in particular in a representative sample of ageing people with ID. Methods: This was an observational cross-sectional study from Wave 1 of Intellectual Disability Supplement to the Irish Longitudinal Study on Ageing; a nationally representative sample of 753 persons with ID aged between 41 and 90 years. Participants/proxy reported medicines (prescription and over the counter) taken on a regular basis; medication data were available for 736 participants (98%). Participants were divided into those with no psychotropic exposure, exposure to 1 psychotropic and psychotropic polypharmacy (2+ psychotropics). Patterns of psychotropic use were analysed. A multinomial logistic regression model identified factors associated with use of 1 psychotropic and psychotropic polypharmacy. Results: Overall, 59.1% (436) of the sample was exposed to any psychotropic; of these, 66.2% reported psychotropic polypharmacy. Antipsychotics were the most frequently reported psychotropic class by 43% of the sample. Living in a residential institution and having a history of reporting a mental health condition or sleep problems were associated with psychotropic polypharmacy after adjusting for confounders, while those with epilepsy were less likely to experience exposure to polypharmacy, but age, gender had no significant effect. Conclusions: Psychotropic use and polypharmacy were commonplace for older adults with ID. Psychotropic use, particularly the use of psychotropic combinations, needs to be regularly reviewed for safety, efficacy and adverse effects, and rationale for use of multiple agents needs to be clear and documented.en
dc.format.extent969en
dc.format.extent983en
dc.language.isoenen
dc.publisherJournal of Intellectual Disability Researchen
dc.relation.ispartofseriesJournal of Intellectual Disability Research;
dc.relation.ispartofseries61;
dc.relation.ispartofseries10;
dc.rightsYen
dc.subjectintellectual disability, mental health, polypharmacy, psychiatric disorders, psychotropic medicinesen
dc.titlePrevalence, patterns and factors associated with psychotropic use in older adults with intellectual disabilities in Irelanden
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/mhenman
dc.identifier.peoplefinderurlhttp://people.tcd.ie/modwyer6
dc.identifier.peoplefinderurlhttp://people.tcd.ie/mccarrm
dc.identifier.rssinternalid171197
dc.identifier.doihttp://dx.doi.org/10.1111/jir.12391
dc.identifier.doi10.1111/jir.12391
dc.rights.ecaccessrightsopenAccess
dc.subject.TCDThemeAgeingen
dc.subject.TCDThemeInclusive Societyen
dc.subject.TCDThemeNeuroscienceen
dc.subject.TCDTagANTI-DEPRESSANT TREATMENTen
dc.subject.TCDTagANTIDEPRESSANT DRUGSen
dc.subject.TCDTagBENZODIAZEPINESen
dc.subject.TCDTagCHRONIC HALOPERIDOL TREATMENTen
dc.subject.TCDTagCHRONIC NEUROLEPTIC TREATMENTen
dc.subject.TCDTagClinical Pharmacyen
dc.subject.TCDTagDRUG TREATMENTen
dc.subject.TCDTagHYPNOTICS, BENZODIAZEPINES, MIDAZOLAMen
dc.subject.TCDTagMEDICATION MANAGEMENTen
dc.subject.TCDTagMEDICATION REVIEWen
dc.subject.TCDTagMEDICATION USEen
dc.subject.TCDTagMENTAL HEALTHen
dc.subject.TCDTagMedication safetyen
dc.subject.TCDTagMental Health Practiceen
dc.subject.TCDTagMental health policy and service provisionen
dc.subject.TCDTagNEUROLEPTIC MEDICATIONen
dc.subject.TCDTagPHARMACOLOGICAL TREATMENTen
dc.subject.TCDTagPHARMACY PRACTICEen
dc.subject.TCDTagPSYCHIATRY OF OLD AGEen
dc.subject.TCDTagPSYCHOTROPICen
dc.subject.TCDTagPsychotropic medicationen
dc.subject.TCDTagmental health and intellectual disabilityen
dc.identifier.orcid_id0000-0002-7922-7691
dc.subject.darat_impairmentAge-related disabilityen
dc.subject.darat_impairmentIntellectual Disabilityen
dc.subject.darat_impairmentMental Health/Psychosocial disabilityen
dc.subject.darat_thematicHealthen
dc.status.accessibleNen
dc.identifier.urihttps://hdl.handle.net/2262/109892


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record